vVARDIS Holding (VVVV) investor relations material

Company overview and business model

• Swiss-founded oral-health platform built around Curodont peptide formulations intended to arrest or reverse early-stage cavities while preserving natural tooth structure.

• Curodont Repair Fluoride Plus is the U.S. flagship and generates most revenue; Curodont Repair is sold in select markets outside the U.S.

• Asset-light model uses third-party manufacturers and distributors; U.S. sales combine a specialized direct sales force with exclusive distributor Henry Schein.

• Products have treated over 3.5 million teeth and reached over 20,000 U.S. dental practices as of June 30, 2026.

Financial performance and metrics

• FY2025 net revenue $30.2M, up 148.5% YoY; gross profit $22.4M and gross margin 74.2%.

• H1 2026 net revenue $28.6M, up 214.2% YoY; gross margin 86.4%, versus 51.4% in H1 2025.

• Net losses were $56.4M in FY2025 and $27.8M in H1 2026; accumulated deficit was $256.3M as of June 30, 2026.

• June 30, 2026 cash and equivalents $29.0M and total loans $84.2M; management said liquidity, operations and offering proceeds should cover requirements for at least 12 months after closing.

• Adjusted EBITDA loss was $23.2M in FY2025 and $11.1M in H1 2026; non-GAAP measure excludes specified costs and gains.

Use of proceeds and capital allocation

• Net proceeds are intended for general corporate purposes, including working capital, operating expenses and capital expenditures; no material acquisition or investment commitments were in place.

• Pending use, proceeds may be invested in short-term, interest-bearing investment-grade securities, certificates of deposit or government securities.

• Selling shareholders receive proceeds from their sales; proceeds from their secondary shares do not increase offering capitalization.